Experts take a deep dive into the latest advancement, exploring groundbreaking clinical trial data, real-world evidence of newly approved therapies, and ongoing research shaping the future of NMIBC, as well as addressing the practical challenges of bringing these innovations into practice.
EP. 5: FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC
May 22nd 2025Panelists discuss how recently FDA-approved therapies, including nadofaragene firadenovec, gemcitabine, and docetaxel, offer alternative treatment options for BCG-unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC), each with distinct mechanisms and administration methods.
EP. 6: An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC
May 22nd 2025Panelists discuss how pembrolizumab, a PD-1 inhibitor, offers a systemic immunotherapy option for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) by enhancing the immune system’s ability to target cancer cells, with intravenous administration and careful monitoring for immune-related adverse effects.
EP. 7: An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
May 29th 2025Panelists discuss how nogapendekin alfa, an intravesical immunotherapy that stimulates a localized immune response, combined with BCG therapy, provides a novel dual approach for treating BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), targeting both local and systemic immune responses.
EP. 8: Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
May 29th 2025Panelists discuss how real-world data from a recent Mayo Clinic study confirms the promising efficacy and favorable safety profile of nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting high cystectomy-free and overall survival rates, with longer follow-up needed to assess response durability.